Anti-CLL-1 antibodies and methods of use
US11466087B2 · kind B2 · utility
0Cited by
26References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 2019 |
| Grant date | Oct 11, 2022 |
| Priority date | — |
| Expiry date | Oct 23, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.